+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Atopic Dermatitis (Atopic Eczema) (Dermatology) - Drugs In Development, 2021

  • PDF Icon

    Drug Pipelines

  • 847 Pages
  • June 2021
  • Region: Global
  • Global Markets Direct
  • ID: 5359573
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Atopic Dermatitis - Drugs In Development, 2021, provides an overview of the Atopic Dermatitis (Dermatology) pipeline landscape.

Atopic dermatitis is an itchy inflammation of skin. Signs and symptoms of atopic dermatitis include red to brownish-gray colored patches, itching, which may be severe, especially at night, small, raised bumps, which may leak fluid and crust over when scratched, thickened, cracked or scaly skin and raw, sensitive skin from scratching. Risk factors include family history of eczema, allergies, hay fever or asthma and gender.

Report Highlights


The publisher's Pharmaceutical and Healthcare latest pipeline guide Atopic Dermatitis - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Atopic Dermatitis (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Atopic Dermatitis (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Atopic Dermatitis (Atopic Eczema) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 9, 6, 57, 37, 4, 81, 28 and 8 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 1, 7 and 3 molecules, respectively.

Atopic Dermatitis (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope


  • The pipeline guide provides a snapshot of the global therapeutic landscape of Atopic Dermatitis (Dermatology).
  • The pipeline guide reviews pipeline therapeutics for Atopic Dermatitis (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Atopic Dermatitis (Dermatology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Atopic Dermatitis (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Atopic Dermatitis (Dermatology)

Reasons to Buy


  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Atopic Dermatitis (Dermatology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Atopic Dermatitis (Dermatology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Introduction
  • Atopic Dermatitis (Atopic Eczema) - Overview
  • Atopic Dermatitis (Atopic Eczema) - Therapeutics Development
  • Atopic Dermatitis (Atopic Eczema) - Therapeutics Assessment
  • Atopic Dermatitis (Atopic Eczema) - Companies Involved in Therapeutics Development
  • Atopic Dermatitis (Atopic Eczema) - Drug Profiles

Atopic Dermatitis (Atopic Eczema) - Dormant Projects
Atopic Dermatitis (Atopic Eczema) - Discontinued Products
  • Atopic Dermatitis (Atopic Eczema) - Product Development Milestones
  • Appendix

List of Tables
  • Number of Products under Development for Atopic Dermatitis (Atopic Eczema), 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Products under Development by Companies, 2021
  • Products under Development by Universities/Institutes, 2021
  • Number of Products by Stage and Target, 2021
  • Number of Products by Stage and Mechanism of Action, 2021
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Atopic Dermatitis (Atopic Eczema) - Pipeline by 3SBio Inc, 2021
  • Atopic Dermatitis (Atopic Eczema) - Pipeline by Abate Med Inc, 2021
  • Atopic Dermatitis (Atopic Eczema) - Pipeline by AbbVie Inc, 2021
  • Atopic Dermatitis (Atopic Eczema) - Pipeline by Abeome Corp, 2021
  • Atopic Dermatitis (Atopic Eczema) - Pipeline by Aclaris Therapeutics Inc, 2021
  • Atopic Dermatitis (Atopic Eczema) - Pipeline by Adare Pharma Solutions, 2021
  • Atopic Dermatitis (Atopic Eczema) - Pipeline by Akaal Pharma Pty Ltd, 2021
  • Atopic Dermatitis (Atopic Eczema) - Pipeline by Akeso Inc, 2021
  • Atopic Dermatitis (Atopic Eczema) - Pipeline by Alexion Pharmaceuticals Inc, 2021
  • Atopic Dermatitis (Atopic Eczema) - Pipeline by Allergy Therapeutics Plc, 2021
  • Atopic Dermatitis (Atopic Eczema) - Pipeline by Almirall SA, 2021
  • Atopic Dermatitis (Atopic Eczema) - Pipeline by Amgen Inc, 2021
  • Atopic Dermatitis (Atopic Eczema) - Pipeline by Amicogen Inc, 2021
  • Atopic Dermatitis (Atopic Eczema) - Pipeline by Amorepacific Corp, 2021
  • Atopic Dermatitis (Atopic Eczema) - Pipeline by Amytrx Therapeutics Inc, 2021
  • Atopic Dermatitis (Atopic Eczema) - Pipeline by Annji Pharmaceutical Co Ltd, 2021
  • Atopic Dermatitis (Atopic Eczema) - Pipeline by AOBiome LLC, 2021
  • Atopic Dermatitis (Atopic Eczema) - Pipeline by Apimeds Inc, 2021
  • Atopic Dermatitis (Atopic Eczema) - Pipeline by Arcutis Biotherapeutics Inc, 2021
  • Atopic Dermatitis (Atopic Eczema) - Pipeline by Arena Pharmaceuticals Inc, 2021
  • Atopic Dermatitis (Atopic Eczema) - Pipeline by Arrien Pharmaceuticals LLC, 2021
  • Atopic Dermatitis (Atopic Eczema) - Pipeline by Asana BioSciences LLC, 2021
  • Atopic Dermatitis (Atopic Eczema) - Pipeline by Aslan Pharmaceuticals Ltd, 2021
  • Atopic Dermatitis (Atopic Eczema) - Pipeline by Astellas Pharma Inc, 2021
  • Atopic Dermatitis (Atopic Eczema) - Pipeline by AstraZeneca Plc, 2021
  • Atopic Dermatitis (Atopic Eczema) - Pipeline by Atrapos Therapeutics LLC, 2021
  • Atopic Dermatitis (Atopic Eczema) - Pipeline by Attillaps Holdings Inc, 2021
  • Atopic Dermatitis (Atopic Eczema) - Pipeline by Avixgen Inc, 2021
  • Atopic Dermatitis (Atopic Eczema) - Pipeline by Azitra Inc, 2021
  • Atopic Dermatitis (Atopic Eczema) - Pipeline by Bausch Health Companies Inc, 2021
  • Atopic Dermatitis (Atopic Eczema) - Pipeline by Beijing Puqi Pharmaceutical Technology Co Ltd, 2021
  • Atopic Dermatitis (Atopic Eczema) - Pipeline by BenevolentAI Ltd, 2021
  • Atopic Dermatitis (Atopic Eczema) - Pipeline by Biomimetix JV LLC, 2021
  • Atopic Dermatitis (Atopic Eczema) - Pipeline by BiomX Inc, 2021
  • Atopic Dermatitis (Atopic Eczema) - Pipeline by Biosion Inc, 2021
  • Atopic Dermatitis (Atopic Eczema) - Pipeline by Nepsone ehf, 2021
  • Atopic Dermatitis (Atopic Eczema) - Pipeline by Neuracle Science Co Ltd, 2021
  • Atopic Dermatitis (Atopic Eczema) - Pipeline by Next Science Ltd, 2021
  • Atopic Dermatitis (Atopic Eczema) - Pipeline by NovaCell Technology Inc, 2021
  • Atopic Dermatitis (Atopic Eczema) - Pipeline by Novan Inc, 2021
  • Atopic Dermatitis (Atopic Eczema) - Pipeline by NovaRock Biotherapeutics Inc, 2021
  • Atopic Dermatitis (Atopic Eczema) - Pipeline by Novartis AG, 2021
  • Atopic Dermatitis (Atopic Eczema) - Pipeline by Numab Therapeutics AG, 2021
  • Atopic Dermatitis (Atopic Eczema) - Pipeline by Oasis Pharmaceuticals LLC, 2021
  • Atopic Dermatitis (Atopic Eczema) - Pipeline by OliX Pharmaceuticals Inc, 2021
  • Atopic Dermatitis (Atopic Eczema) - Pipeline by Ondek Pty Ltd, 2021
  • Atopic Dermatitis (Atopic Eczema) - Pipeline by Oneness Biotech Co Ltd, 2021
  • Atopic Dermatitis (Atopic Eczema) - Pipeline by Orgenesis Inc, 2021
  • Atopic Dermatitis (Atopic Eczema) - Pipeline by Otsuka Holdings Co Ltd, 2021
  • Atopic Dermatitis (Atopic Eczema) - Pipeline by Panolos Bioscience, 2021
  • Atopic Dermatitis (Atopic Eczema) - Pipeline by Pantherics Inc, 2021
  • Atopic Dermatitis (Atopic Eczema) - Pipeline by PeLeMed Co Ltd, 2021
  • Atopic Dermatitis (Atopic Eczema) - Pipeline by Pfizer Inc, 2021
  • Atopic Dermatitis (Atopic Eczema) - Pipeline by Provectus Biopharmaceuticals Inc, 2021
  • Atopic Dermatitis (Atopic Eczema) - Dormant Projects, 2021
  • Atopic Dermatitis (Atopic Eczema) - Discontinued Products, 2021

List of Figures
  • Number of Products under Development for Atopic Dermatitis (Atopic Eczema), 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Number of Products by Top 10 Targets, 2021
  • Number of Products by Stage and Top 10 Targets, 2021
  • Number of Products by Top 10 Mechanism of Actions, 2021
  • Number of Products by Stage and Top 10 Mechanism of Actions, 2021
  • Number of Products by Top 10 Routes of Administration, 2021
  • Number of Products by Stage and Top 10 Routes of Administration, 2021
  • Number of Products by Top 10 Molecule Types, 2021
  • Number of Products by Stage and Top 10 Molecule Types, 2021

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • 3SBio Inc
  • Abate Med Inc
  • AbbVie Inc
  • Abeome Corp
  • Aclaris Therapeutics Inc
  • Adare Pharma Solutions
  • Akaal Pharma Pty Ltd
  • Akeso Inc
  • Alexion Pharmaceuticals Inc
  • Allergy Therapeutics Plc
  • Almirall SA
  • Amgen Inc
  • Amicogen Inc
  • Amorepacific Corp
  • Amytrx Therapeutics Inc
  • Annji Pharmaceutical Co Ltd
  • AOBiome LLC
  • Apimeds Inc
  • Arcutis Biotherapeutics Inc
  • Arena Pharmaceuticals Inc
  • Forte Biosciences Inc
  • Provectus Biopharmaceuticals Inc
  • Pyramid Biosciences Inc
  • Qurient Co Ltd
  • Ralexar Therapeutics Inc
  • RAPT Therapeutics Inc
  • Regeneron Pharmaceuticals Inc
  • Regeneus Ltd
  • Rhizen Pharmaceuticals SA
  • Ribomic Inc